Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2013

Beltran H, Yelensky R, Frampton GM, Park K, Downing SR, MacDonald TY, et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol. 2013;63(5):920-6.

Piotti KC, Scognamiglio T, Chiu R, Chen Y-. Expression of cancer/testis (CT) antigens in squamous cell carcinoma of the head and neck: evaluation as markers of squamous dysplasia. Pathol Res Pract. 2013;209(11):721-6.

Martz J, Jain S, Vahdat LT, Qin L, Mosquera JM, Antonescu CR, et al. High-grade KIT-negative sarcoma of the small bowel in a patient with chronic myeloid leukemia receiving long-term tyrosine kinase inhibitors. J Clin Oncol. 2013;31(11):e181-5.

Penney KL, Stampfer MJ, Jahn JL, Sinnott JA, Flavin R, Rider JR, et al. Gleason grade progression is uncommon. Cancer Res. 2013;73(16):5163-8.

Kauffman EC, Robinson BD, Downes M, Marcinkiewicz K, Vourganti S, Scherr DS, et al. Estrogen receptor-β expression and pharmacological targeting in bladder cancer. Oncol Rep. 2013;30(1):131-8.

Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, Drier Y, et al. Punctuated evolution of prostate cancer genomes. Cell. 2013;153(3):666-77.

Hannah J, Zhou P-. The CUL4A ubiquitin ligase is a potential therapeutic target in skin cancer and other malignancies. Chin J Cancer. 2013;32(9):478-82.

Brait M, Maldonado L, Noordhuis MG, Noordhuis M, Begum S, Loyo M, et al. Association of promoter methylation of VGF and PGP9.5 with ovarian cancer progression. PLoS One. 2013;8(9):e70878.

Voena C, Di Giacomo F, Panizza E, D'Amico L, Boccalatte FE, Pellegrino E, et al. The EGFR family members sustain the neoplastic phenotype of ALK+ lung adenocarcinoma via EGR1. Oncogenesis. 2013;2:e43.

Tiacci E, Schiavoni G, Martelli MP, Boveri E, Pacini R, Tabarrini A, et al. Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia. Haematologica. 2013;98(4):635-9.